Switch theme
Sign up to access all valuation multiples
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
1996
n/a
Last FY Revenue $1K
Last FY EBITDA $0.5M
-$6.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, NUTEX achieved revenue of $1K and an EBITDA of $0.5M.
NUTEX expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NUTEX valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1K | XXX | XXX | XXX |
| Gross Profit | XXX | $1K | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | $0.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 39570% | XXX | XXX | XXX |
| EBIT | XXX | -$0.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -4644% | XXX | XXX | XXX |
| Net Profit | XXX | $0.5M | XXX | XXX | XXX |
| Net Margin | XXX | 38028% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NUTEX's stock price is HUF 17 (or $0).
NUTEX has current market cap of HUF 2.7B (or $7.5M), and EV of -HUF 2.4B (or -$6.6M).
See NUTEX trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$6.6M | $7.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NUTEX has market cap of $7.5M and EV of -$6.6M.
NUTEX's trades at -5272.9x EV/Revenue multiple, and -13.3x EV/EBITDA.
Equity research analysts estimate NUTEX's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NUTEX's P/E ratio is not available.
See valuation multiples for NUTEX and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.5M | XXX | $7.5M | XXX | XXX | XXX |
| EV (current) | -$6.6M | XXX | -$6.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -5272.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 113.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 15.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNUTEX's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
NUTEX's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NUTEX's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NUTEX and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 39570% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4744% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NUTEX acquired XXX companies to date.
Last acquisition by NUTEX was XXXXXXXX, XXXXX XXXXX XXXXXX . NUTEX acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NUTEX founded? | NUTEX was founded in 1996. |
| Where is NUTEX headquartered? | NUTEX is headquartered in Hungary. |
| Is NUTEX publicy listed? | Yes, NUTEX is a public company listed on BUD. |
| What is the stock symbol of NUTEX? | NUTEX trades under NUTEX ticker. |
| When did NUTEX go public? | NUTEX went public in 1996. |
| Who are competitors of NUTEX? | Similar companies to NUTEX include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of NUTEX? | NUTEX's current market cap is $7.5M |
| Is NUTEX profitable? | Yes, NUTEX is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
